Key result
AVR remains optimal for calcified aortic stenosis as targeted drugs fail to slow disease progression.
Why the study?
No targeted drug has been proven to slow down or prevent the progression of calcified aortic stenosis, leaving aortic valve replacement as the only optimal treatment.
This review highlights the complex pathobiology of calcified aortic stenosis and emphasizes that aortic valve replacement remains the only definitive treatment while proposing novel therapeutic targets.
Answers are grounded in this paper and cite their sources.
AVR remains standard for calcified aortic stenosis; leaves open targeted pharmacotherapy pending prospective trials.
Calcified aortic stenosis (AS) is one of the most common valvular heart diseases worldwide, characterized by progressive fibrocalcific remodeling and thickening of the leaflets, which ultimately leads to obstruction of blood flow. Its pathobiology is an active and complicated process, involving endothelial cell dysfunction, lipoprotein deposition and oxidation, chronic inflammation, phenotypic transformation of valve interstitial cells, neovascularization, and intravalvular hemorrhage. To date, no targeted drug has been proven to slow down or prevent disease progression. Aortic valve replacement is still the optimal treatment of AS. This article reviews the etiology, diagnosis, and management of calcified aortic stenosis and proposes novel potential therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2024) conducted a review in Calcified aortic stenosis. Aortic valve replacement remains the optimal treatment for calcified aortic stenosis, as no targeted drug has been proven to slow or prevent disease progression.
Synapse has enriched 10 related papers. Consider them for comparative context: